[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418539":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":21,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":7,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Kang Stem Biotech Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"OTHER","Not applicable(observational study)",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Eundoek Yeo","CONTACT","82-2-888-1592","edyeo@kangstem.com",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Seulbi Lee","sblee@kangstem.com",[22],{"facility":23,"status":7,"city":24,"state":7,"zip":7,"country":25,"countryCode":7,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Dongguk University Medical Center","Ilsan","South Korea",{"type":27,"coordinates":28},"Point",[29,30],129.43333,35.5,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100418539","long-term-follow-up-study-to-evaluate-the-safety-and-explore-the-efficacy-of-multiple-doses-of-furestem-ad-inj-100418539",false,"NCT04730024","Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj","Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results From the K0104 Extension Study","Inclusion Criteria:\n\n1. Subject who enrolled K0104 Clinical Trial(parent study).\n2. Subjects who understand and voluntarily sign an informed consent form\n\nExclusion Criteria:\n\n1. Subjects who are expected to be unable to perform at least one follow-up during this study (K0104-E)\n2. Subjects who has received\u002Fadministered clinical trial drugs or medical devices by participating in other clinical trials until the first visit of this trial (K0104-E) after the completion of K0104 clinical trial\n3. Subjects who are judged to be unsuitable for other researchers to participate in the research","ALL","19 Years",{"count":44,"type":45},102,"ESTIMATED","OBSERVATIONAL","A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study",[49],"Atopic Dermatitis","NOT_YET_RECRUITING","2021-01-25",{"date":53,"type":54},"2021-01-29","ACTUAL",{"date":56,"type":45},"2022-03-27",{"date":58,"type":45},"2030-06-30",{"name":5,"class":6},1]